Molecular Identity of GHK-Cu
Glycyl-L-histidyl-L-lysine copper(II) complex — abbreviated GHK-Cu — is a naturally occurring tripeptide–metal chelate first isolated from human plasma by Pickart and Thaler in 1973 (Nature New Biology). The parent tripeptide GHK (Gly-His-Lys; CAS 49557-75-7) demonstrates high-affinity binding for cupric ions (Cu²⁺) with a stability constant (log K) of approximately 16.4, among the highest measured for a simple tripeptide (Perkins et al., 1999, Journal of Inorganic Biochemistry). At physiological pH, the complex adopts a square-planar geometry coordinated through the histidine imidazole nitrogen (N3), the glycine α-amino group, and the deprotonated amide nitrogen of the Gly-His peptide bond, with an exchangeable axial water molecule completing the coordination sphere.
For research purposes only. Not for human consumption.
Copper Coordination Chemistry
The coordination geometry of GHK-Cu has been characterized by X-ray absorption spectroscopy (XAS), including extended X-ray absorption fine structure (EXAFS) and X-ray absorption near edge structure (XANES) analyses. Copper in GHK-Cu exists predominantly in the Cu²⁺ (cupric) oxidation state under aerobic aqueous conditions, with a characteristic square-planar 3N1O coordination environment confirmed by:
- Cu–N(imidazole) bond length: ~1.98 Å
- Cu–N(amino terminal) bond length: ~2.04 Å
- Cu–N(deprotonated amide) bond length: ~1.92 Å
- Cu–O(water) axial: ~2.20 Å
These parameters are consistent with a 4N square-planar geometry transitioning to 3N1O with partial Jahn-Teller distortion at physiological ionic strength. The high thermodynamic stability of the complex reflects the chelate effect: multidentate ligands form more stable complexes than equivalent monodentate ligands due to the entropic advantage of ring closure upon binding.
Under reducing conditions (e.g., in the presence of ascorbate), Cu²⁺ can be transiently reduced to Cu⁺ (cuprous), enabling redox cycling that may participate in superoxide dismutase (SOD)-mimetic activity observed in vitro. This redox chemistry is mechanistically relevant to the compound's antioxidant properties studied in cell-free assays.
Plasma Concentration and Endogenous Context
GHK is endogenously present in human plasma at concentrations of approximately 200 ng/mL (≈ 0.4 µM) in young adults, declining with age to ~80 ng/mL by age 60 (Pickart, 2008, Journal of Biomedicine and Biotechnology). This age-associated decline has prompted extensive investigation into GHK's potential roles in tissue homeostasis signaling pathways. Total plasma copper is maintained at 70–140 µg/dL (11–22 µM) in healthy individuals, with approximately 65% bound to ceruloplasmin and the remainder associated with albumin and low-molecular-weight complexes including GHK.
Gene Expression Studies: Transcriptomic Data
The most extensive transcriptomic characterization of GHK-Cu effects was reported by Pickart, Vasquez-Soltero, and Margolina (2015, BioMed Research International), utilizing the Broad Institute Connectivity Map (CMap) platform to analyze genome-wide expression changes in MCF7 cells treated with GHK. Key findings included modulation of 31 genes associated with collagen synthesis pathways, 30 genes in the TGF-β superfamily signaling network, and 22 genes related to antioxidant enzyme expression.
Collagen and Extracellular Matrix Genes
Upregulated transcripts in GHK-treated research models include:
- COL1A1, COL1A2 — genes encoding the α1 and α2 chains of Type I collagen, the predominant structural protein of dermis, bone, and tendon.
- COL3A1 — Type III collagen, expressed in early-stage wound matrix deposition.
- ELN — elastin gene expression associated with elastic fiber assembly.
- MMP2 — matrix metalloproteinase 2, a gelatinase involved in type IV collagen remodeling; paradoxical co-upregulation with collagens reflects matrix remodeling rather than simple accumulation.
TGF-β Pathway Modulation
The TGF-β (Transforming Growth Factor-beta) superfamily constitutes a master regulator of fibroblast activity, extracellular matrix production, and cellular differentiation. Transcriptomic studies identified GHK as modulating:
- TGFB1 — ligand upregulation, consistent with increased autocrine/paracrine fibroblast activation signals.
- SMAD3 — canonical downstream transcription factor in TGF-β/SMAD signaling axis.
- LTBP1 — latent TGF-β binding protein 1, controlling extracellular TGF-β bioavailability.
Antioxidant Response Element (ARE) Pathway
GHK has been shown to upregulate NRF2 (Nuclear factor erythroid 2-related factor 2) target genes in research cell culture studies, including:
- SOD1, SOD2 — cytoplasmic and mitochondrial superoxide dismutases.
- GPX1 — glutathione peroxidase 1.
- CAT — catalase.
- HMOX1 — heme oxygenase 1, a stress-responsive cytoprotective enzyme.
NRF2 activation involves GHK-mediated disruption of the NRF2–KEAP1 inhibitory complex, allowing NRF2 nuclear translocation and ARE-driven transcription, analogous to mechanisms described for other endogenous metallopeptide signaling molecules.
VEGF and Angiogenic Signaling
Research in human fibroblast and endothelial cell cultures has documented GHK-Cu-induced upregulation of VEGF (Vascular Endothelial Growth Factor) mRNA and protein, mediated in part through SP1 and HIF-1α transcription factor binding sites within the VEGF promoter. The mechanistic hypothesis involves copper-dependent modulation of hypoxia-inducible factor prolyl hydroxylase (PHD) activity — Cu²⁺ ions compete with Fe²⁺ at the enzyme catalytic center, potentially stabilizing HIF-1α and initiating downstream VEGF transcription even under normoxic conditions (Trackman & Kagan, 1979; updated in Grubman & Bhatt, 2021 reviews).
p53 Tumor Suppressor Pathway Research
A notable transcriptomic observation from Pickart et al. (2015) was apparent GHK modulation of p53 network genes, including upregulation of CDKN1A (p21/CIP1), a cyclin-dependent kinase inhibitor and direct p53 transcriptional target. This observation has prompted investigation into GHK's potential role in DNA damage response signaling, though mechanistic characterization remains incomplete and requires further preclinical study.
Nervous System Research Context
Nerve Growth Factor (NGF) expression upregulation by GHK has been reported in vitro, with proposed involvement of the TrkA (NTRK1) signaling pathway. Additionally, GHK modulates expression of BDNF (Brain-Derived Neurotrophic Factor) and components of the Wnt/β-catenin pathway in neuroblastoma cell research models, suggesting potential utility as a research tool for investigating neuropeptide–neurotrophin crosstalk.
Pharmacokinetic Profile
GHK-Cu is relatively stable in aqueous solution compared to many other tripeptides due to the chelation-mediated conformational constraint imposed by Cu²⁺ coordination. However, it remains susceptible to dipeptidyl peptidase (DPP) and aminopeptidase activity. The peptide component (GHK) is cleared rapidly from plasma (t½ ~2–4 hours in rodent studies), while the copper dissociates and enters cellular copper trafficking pathways mediated by the copper chaperone ATOX1 and CTR1 transporter proteins.
Research Applications
GHK-Cu is employed as a research tool in studies of:
- Copper metalloenzyme reconstitution assays
- Fibroblast gene expression profiling
- ECM remodeling pathway interrogation
- NRF2/KEAP1 interaction studies
- Angiogenesis in vitro models (tube formation assays, VEGF ELISA)
Lumevara offers GHK-Cu for qualified research use. All material is accompanied by third-party Certificate of Analysis confirming ≥98% purity by RP-HPLC and ESI-MS molecular weight verification.
Disclaimer: For research purposes only. Not for human consumption. These statements have not been evaluated by the FDA.